Article - 17/02/2021 Whole blood model enables development of early warning system for sepsis Sepsis is a life-threatening disease that can be treated all the more successfully the faster therapy is initiated. It is not just the infection itself that is so dangerous, but a dysregulated response of the immune system. Physicians at Ulm University Hospital have now developed an animal-free test system that can be used to research the disease and develop innovative diagnostic tools to quickly assess a patient's sepsis risk and optimise…https:////www.gesundheitsindustrie-bw.de:443/en/article/news/whole-blood-model-enables-development-early-warning-system-sepsis
Article - 14/01/2021 Newly discovered RNA as growth driver in liver cancer Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.https:////www.gesundheitsindustrie-bw.de/en/article/news/newly-discovered-rna-growth-driver-liver-cancer
Infection control - 07/01/2021 Gene accordions as potential markers for pathogenic properties Bacteria must react to changes in the environment in order to survive. This is partly done by adapting genetic material, for example by multiplying and shortening individual genome segments. The research group led by Dr. Simon Heilbronner from the Interfaculty Institute of Microbiology and Infection Medicine at the University of Tübingen has shown that these so-called gene accordions are frequently found in the bacterium Staphylococcus aureus.https:////www.gesundheitsindustrie-bw.de/en/article/news/gene-accordions-potential-markers-pathogenic-properties
Press release - 17/11/2020 The Long Road to Dementia The chain reaction which leads to toxic protein deposits in Alzheimer’s disease starts even earlier than assumed. Researchers from Tübingen show how this process could be stopped early on.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/long-road-dementia
Press release - 02/11/2020 Juvenile myelomonocytic leukemia: International classification model allows for customized treatment Juvenile myelomonocytic leukemia (JMML) is a rare blood cancer of early childhood. Previous research activities have shown that JMML patients can be divided into three groups based on certain genetic markers, DNA methylation. Depending on the subgroup, statements can be made about the course of the disease. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/juvenile-myelomonocytic-leukemia-international-classification-model-allows-customized-treatment
Press release - 31/08/2020 Radiology researcher receives Humboldt Foundation Sofja Kovalevskaja Award Dr. André Martins from the Department of Radiology at the Tübingen University Hospitals is one of this year's recipients of the Alexander von Humboldt Foundation's Sofja Kovalevskaja Award.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/radiology-researcher-receives-humboldt-foundation-sofja-kovalevskaja-award
Press release - 27/04/2020 EIT Health pledges €6m funding to accelerate COVID-19 solutions EIT Health has announced over €6m of funding in the fight against COVID-19. The funding will be dedicated to 14 specially selected health innovation projects across Europe which will focus on immediate and impactful solutions that can be found to arm health services with better tools in navigating the pandemic.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/eit-health-pledges-eur6m-funding-accelerate-covid-19-solutions
New edition - 24/05/2019 Tumour metastasis Cancer is usually not curable when metastases have formed in the body. Metastases are often resistant to drugs that have successfully eliminated the primary tumour. The basic features of the complex process of metastasis are now known, but many details still remain elusive. Intensive research activities are focusing on new therapeutic concepts aimed at developing effective anti-metastatic therapies.https:////www.gesundheitsindustrie-bw.de/en/article/dossier/tumour-metastasis
Article - 16/04/2019 Tumour monitoring using liquid biopsy Liquid biopsy, the analysis of cancer biomarkers and circulating tumour cells in body fluids such as blood, is revolutionising the diagnosis and monitoring of cancer. It has also been possible to expand circulating tumour cells from the blood under laboratory conditions. It is expected that in the future, liquid biopsy will be able to precisely characterise tumour cells at every stage of a cancer.https:////www.gesundheitsindustrie-bw.de/en/article/news/tumour-monitoring-using-liquid-biopsy
Article - 22/03/2019 Personalised therapies for treating metastasing breast cancer Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.https:////www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
Biosensor - 13/11/2018 Rapid medical test for at-home use For quite a number of illnesses, patients need to have the concentrations of the medications they are taking and their blood metabolites checked on a regular basis, which can make life rather difficult. Researchers at the Max Planck Institute for Medical Research in Heidelberg have now developed a test based on the firefly enzyme luciferase. This enzyme can be used to quickly and cheaply measure parameters of interest.https:////www.gesundheitsindustrie-bw.de/en/article/news/rapid-medical-test-for-at-home-use
Dossier - 28/08/2018 With molecular diagnostics to biomarker-based personalised therapy Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.https:////www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
Expert interview - 08/08/2018 Ludolph: diagnosing and treating neurodegenerative disorders Ulm has long been a world leader in diagnosing and treating rare neurological disorders, notably amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Huntington's disease (HD). We spoke with Professor Albert C. Ludolph, spokesperson for the Ulm DZNE site, medical director of the Clinic for Neurology at the RKU (University and Rehabilitation Clinics of Ulm) and world-renowned ALS researcher.https:////www.gesundheitsindustrie-bw.de/en/article/news/ludolph-diagnosing-and-treating-neurodegenerative-disorders
Press release - 04/10/2017 Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies Tuebingen, Germany and Houston, Texas, October 4, 2017 – Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-receives-58-million-in-financing-to-develop-t-cell-receptor-based-immunotherapies
Press release - 05/09/2017 Cell marking opens up a window into the body A new and particularly reliable method for marking cells can simplify research into diseases such as myocardial infarction, diabetes or Alzheimer's and reduce the use of test animals: Scientists from the University of Tübingen have developed a method by which they can target specific cell types in mice and monitor their behavior using positron emission tomography (PET). PET-based cell tracking allows scientists to observe complex life…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/cell-marking-opens-up-a-window-into-the-body
Article - 04/07/2017 Ruxolitinib – successful graft-versus-host disease treatment Graft-versus-host disease is a serious complication in leukaemia patients who have been given a blood stem cell transplant from a genetically different person. Prof. Dr. Nikolas von Bubnoff and Prof. Dr. Robert Zeiser from the Department of Haematology, Oncology and Stem Cell Transplantation at Freiburg University Medical Centre initiated a Germany-wide study to show that an active substance called ruxolitinib has a promising therapeutic effect.…https:////www.gesundheitsindustrie-bw.de/en/article/news/ruxolitinib-successful-graft-versus-host-disease-treatment
Press release - 24/05/2017 High-Tech Gründerfonds (HTGF) invests in Reutlingen-based SIGNATOPE GmbH – Safe medications thanks to new test procedures High-Tech Gründerfonds is investing EUR 600,000 in Reutlingen-based SIGNATOPE GmbH. SIGNATOPE will use the funds to advance the development of its unique biomarker assay system, that has been established to support pharmaceutical research. The technology is based on special antibodies and allows the early detection of possible side effects during the drug development process. Thereby, the need for animal testing will be reduced while the drug…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/high-tech-gruenderfonds-htgf-invests-in-reutlingen-based-signatope-gmbh-safe-medications-thanks-to-new-test-procedures
Article - 18/05/2017 ImmuStick – novel rapid test for identifying disease pathogens In some situations such as in the food and pharmaceutical industries or hospitals, a test to identify disease pathogens can be vital. At present, such tests are relatively time-consuming and can take hours or even days to produce results, depending on the pathogen. Scientists from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart are currently developing a rapid test called ImmuStick which is as easy to use…https:////www.gesundheitsindustrie-bw.de/en/article/news/immustick-novel-rapid-test-for-identifying-disease-pathogens
Article - 31/03/2017 Bosch to enter the medical technology sector – start-up culture meets proven expertise Many of us have known the Bosch Group mainly as a technology company that is active in the automotive sector. Now, the multinational company is opening up a whole new field of business and is entering the medical technology market with a new subsidiary. Bosch Healthcare Solutions GmbH, which is headquartered in the city of Waiblingen, has developed an innovative breath analysis device that allows asthmatics to measure the severity of airway…https:////www.gesundheitsindustrie-bw.de/en/article/news/bosch-to-enter-the-medical-technology-sector-start-up-culture-meets-proven-expertise
Article - 27/02/2017 Michael Baumann – the new man at the helm of the DKFZ On 1st November 2016, Professor Michael Baumann, a radiation oncologist from Dresden, became the new chairman and scientific director of the German Cancer Research Center in Heidelberg. Michael Baumann has the perfect background when it comes to combining basic and applied cancer research. This enables scientific findings to be used more quickly and effectively for preventing, diagnosing and treating cancer, and patients’ individual needs to be…https:////www.gesundheitsindustrie-bw.de/en/article/news/michael-baumann-the-new-man-at-the-helm-of-the-dkfz
Article - 21/12/2016 For all types of tests: Signatope’s biomarker assays Signatope is a new biotech company that has been offering innovative biomarker assays for application in drug discovery since August 2016. The company’s assays can be used in all phases of drug development to detect potential adverse drug effects on the kidneys, liver and other organs in any species whatsoever using minute amounts of sample.https:////www.gesundheitsindustrie-bw.de/en/article/news/for-all-types-of-tests-signatopes-biomarker-assays
Article - 13/12/2016 Smart sensor technology from Ulm can do more than just breath analysis Detecting disease-specific molecules in human breath is technically feasible, but time-consuming and rather costly. "µbreath" could soon change this. The breath gas analysis device has all the necessary requirements for commercial success in the healthcare sector: it is compact, accurate, highly sensitive and fast. The chemist who developed µbreath, Prof. Boris Mizaikoff from Ulm University, and his partners are hoping to start…https:////www.gesundheitsindustrie-bw.de/en/article/news/smart-sensor-technology-from-ulm-can-do-more-than-just-breath-analysis
Article - 12/09/2016 New target for the therapy of hepatocellular carcinoma discovered Hepatocellular carcinoma is the second most common cause of cancer deaths worldwide. If the tumour is at an advanced stage, doctors have few treatment options. Researchers led by Prof. Dr. Lars Zender from the University of Tübingen have now identified one of the cancer's Achilles' heels, namely, the interaction between C-MYC and AURKA proteins, which can be destabilised with a drug, thus killing cancer cells. https:////www.gesundheitsindustrie-bw.de/en/article/news/new-target-for-the-therapy-of-hepatocellular-carcinoma-discovered
BioLAGO and BIOPRO to start new diagnostics project - 07/07/2016 DiagNeeds: translating clinical requirements into new products (Lake Constance/Stuttgart) – BioLAGO e.V. and BIOPRO Baden-Württemberg GmbH are working together on the “DiagNeeds” project to bring hospitals and medical professionals closer to diagnostics providers in order to facilitate the development of new diagnostic procedures. There will be special focus on topics that are currently of major interest in the field of diagnostics, including liquid biopsies, companion diagnostics, point-of-care diagnostics…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/diagneeds-klinik-bedarfe-in-neue-produkte-uebersetzen
Article - 25/04/2016 Pancreatic cancer and its resistance to therapy Pancreatic tumours are among the cancers with the worst prognosis. In many cases they are resistant to treatment. Prof. Dr. Andreas Trumpp and his colleagues from the DKFZ and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine HI-STEM have discovered that the reason why some pancreatic tumours are so resistant to treatment is down to larger quantities of the enzyme CYP3A5 in subtypes of pancreatic cancer. Molecular…https:////www.gesundheitsindustrie-bw.de/en/article/news/pancreatic-cancer-and-its-resistance-to-therapy